Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19035644 | 0.93 | CHRNA7 (0.51) | CHRNA7DRD4KCNH2SIGMAR1DRD2 | |
| SCHEMBL7423220 | 0.90 | OPRD1 (0.60) | CHRNA7DRD4KCNH2SIGMAR1DRD2 | |
| SCHEMBL24508006 | 0.82 | KDM4E (0.56) | CHRNA7DRD4KCNH2SIGMAR1DRD2 | |
| SCHEMBL17194427 | 0.81 | MAPT (0.51) | CHRNA7DRD4SIGMAR1MAPTKDM4E | |
| SCHEMBL3263264 | 0.81 | MAPT (0.43) | CHRNA7DRD4KCNH2SIGMAR1DRD2 | |
| SCHEMBL9006349 | 0.81 | KCNH2 (0.62) | CHRNA7DRD4KCNH2SIGMAR1DRD2 | |
| SCHEMBL6550226 | 0.81 | MAPT (0.61) | CHRNA7SIGMAR1MAPTCYP2D6KDM4E | |
| SCHEMBL27448978 | 0.81 | CHRNA7 (0.63) | CHRNA7DRD4KCNH2SIGMAR1DRD2 | |
| SCHEMBL1412431 | 0.81 | CHRNA7 (0.58) | CHRNA7DRD4KCNH2SIGMAR1DRD2 | |
| SCHEMBL5071643 | 0.81 | CHRNA7 (0.58) | CHRNA7DRD4KCNH2SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300370-B1 | SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES | EXXONMOBIL RES & ENG CO (US) | 2014-06-18 | — | — | EP | claimed |
| CN-102066259-B | Synthesis and use of MSE framework type molecular sieves | EXXONMOBIL RES & ENG CO | 2014-01-15 | — | — | CN | claimed |
| US-8034253-B2 | Decontaminant | BATTELLE MEMORIAL INSITUTE (US) | 2011-10-11 | — | — | US | claimed |
| JP-2011524848-A | — | — | 2011-09-08 | — | — | JP | claimed |
| CN-102066259-A | Synthesis and use of MSE framework type molecular sieves | EXXONMOBIL RES & ENG CO | 2011-05-18 | — | — | CN | claimed |
| EP-1846111-B1 | DECONTAMINANT | BATTELLE MEMORIAL INSTITUTE (US) | 2011-04-13 | — | — | EP | claimed |
| EP-2300370-A2 | SYNTHESIS AND USE OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES | ExxonMobil Research and Engineering Company (US) | 2011-03-30 | — | — | EP | claimed |
| EP-1428822-B1 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-15 | — | — | EP | claimed |
| US-20090318696-A1 | Synthesis and use of MSE-framework type molecular sieves | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2009-12-24 | — | — | US | claimed |
| WO-2009154783-A2 | SYNTHESIS AND USE OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2009-12-23 | — | — | WO | claimed |
| EP-1240141-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2003-11-19 | — | — | EP | claimed |
| CN-1420869-A | Novel modulators of dopamine neurotransmission | CARLSSON A RESEARCH AB (SE) | 2003-05-28 | — | — | CN | claimed |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2003-01-02 | — | — | US | claimed |
| EP-0675118-B1 | Biphenylderivatives, process for their preparation and their use as medicaments | EISAI CO LTD (JP) | 2002-10-09 | — | — | EP | claimed |
| EP-1240143-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | claimed |
| WO-2001046146-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | claimed |
| EP-0675118-A2 | Biphenylderivatives, process for their preparation and their use as medicaments | Eisai Co., Ltd. (JP) | 1995-10-04 | — | — | EP | claimed |
| US-10799492-B2 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2020-10-13 | — | — | US | disclosed |
| US-5089497-A | Dopaminergic agents | WARNER-LAMBERT COMPANY (US) | 1992-02-18 | — | — | US | disclosed |
| WO-1990004969-A1 | NOVEL AZT ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1990-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318696-A1 | Synthesis and use of MSE-framework type molecular sieves | ETV6, TERF2, ASF1A | CHRNA7 3259/4885DRD4 1541/4885KCNH2 462/4885 |
| US-10799492-B2 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers | DRD2, HTT, DRD4 | CHRNA7 926/4885DRD4 3/4885KCNH2 978/4885 |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | CHRNA7 6/4885DRD4 19/4885KCNH2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.